AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 MAY 5 - (NewsRx.com & NewsRx.net) -- ATRA and TSA are therapeutically useful in patients with acute leukemia displaying the MLL-AF9 fusion gene.
In acute "leukemia patients with MLL (mixed linage leukemia), rearrangements tend to respond poorly to conventional therapies." The "differentiation of human myeloid leukemia cells displaying the MLL-AF9 gene" was examined "using several differentiation agents," wrote scientists from Japan.
"When MOLM-14 cells were treated with all-trans retinoic acid (ATRA) or 1beta, 25-dihydroxyvitamin D3, significant induced differentiation was observed. Trichostatin A (TSA), an inhibitor of histone deacetylase, demonstrated enhanced effects with ATRA in regard to growth inhibition and differentiation induction in MOLM-14 cells. Pretreatment with TSA before exposure to ATRA displayed increased effect," K. Iijima reported.
"Based on these findings, combined treatment with ATRA and TSA may be clinically ...
Source: HighBeam Research, ATRA and TSA therapy useful in acute leukemia displaying MLL-AF9...